copyright DAYTRADERBUSINESS.COM- TRADE SUR BIOCUREX Avril 2004

BioCurex (OTCBB: BOCX) vient d'indiquer ses plans stratégiques vendredi soir · Des résultats impressionnants sur la détection du cancer des poumons avec le serum RECAF un test sanguin qui a été annoncé lundi matin. (voir détails en bas).

Le management a travaillé avec intelligence et avec succès pour amener le support et d'investisseurs potentiels et futures partenaires. Très recemment la valeur a réagit sur un mouvement de quelques couvertures de positions à découvert (short covering) . Des résultats récents et d'autres à venir vont continuer à valider la technologie et le potentiel de cette société.

Quelques chiffres : Inutile de dire, les actions ont augmenté plus et plus rapidement que n'importe qui aurait pu prévoir. Pendant que nous croyons cela il pourrait y avoir quelque retournement à la baisse à ces niveaux, il y n'a pas de doute à long terme, la commercialisation de la technologie diagnostique de BioCurexs pourrait produire des résultats énormes.

Comme aujourd'hui la capitalisation du marché fait plafonner la société à 25 millions de $, la commercialisation de sa technologie dans les marchés de test de cancer --ceux valent des milliards de dollars par an de chiffre d'affiaire-- l'achat à long terme est rendu obligatoire. Cela a dit, pour les lecteurs de notre lettre qui ont suivi nos précédents conseils sur ce genre de valeur à haut potentiel de grand bénéfices ont été noté.

Les investisseurs voudront posséder cette action pour les plus futures annonces, de partenaire(s) potentiel(s) et les possibles alliances à venir. Nous aurons une évaluation plus détaillée de cette société de ces activités dans un avenir proche, mais pour le moment, il est important d'indiquer que la prise en considération de la technologie et des développements potentiels en avenir sont extrêmement encourageants.

Ces derniers mois l'actualité a été assez calme. Avec les résultats en ce qui concerne la compagnie les tests de biopsie d'Histo-RECAF au japon et France vont bientôt être annoncée, et on parle d'investisseurs potentiels et de partenaires stratégiques, BioCurex s'est déplacé sur les écrans de radar d'investisseur, pas avec progression progressive mais d'un coup. Et nous croyons que les fortunes de cette compagnie singulière continueront à augmenter sur les semaines et les mois prochains. La commercialisation de la technologie de BioCurex est simplement la première étape dans le développement à long terme de thérapies de cancer et de traitements à venir. La patience a été une stratégie extrêmement valorisante pour les investisseurs de cettesociété bien que, jusqu'à ce que récemment, quasiment rien n'a été rendu publique. Comme nous avons dit,ce qui va changer évidemment et comme encore plus d'infos , nous vous en tiendrons informé.. Pour le moment, merci prendre quelques moments pour lire les 2 communiqués de presse ci-dessous.

Press release #1

BioCurex: Aggressively Moves Ahead with 2004 Strategic Plan Friday April 2, 4:56 pm ET RANCHO SANTA MARGARITA, Calif.--(BUSINESS WIRE)--

April 2, 2004--Dr. Ricardo Moro, President and CEO, BioCurex Inc. (OTCBB:BOCX - News) released the company's corporate forecast for 2004. The core of BioCurex's technology is the discovery and subsequent patenting related to a molecule found on cancer cells that is practically absent from normal cells or benign tumor cells. The molecule serves as a cancer "marker" that is found on the surface as well as inside a cancer cell. The company has called it RECAF(TM).

Initially, the company developed and reported on a tissue test (Histo-RECAF) and received FDA recognition for its ability to detect cancer cells. The product development and subsequent approval provided early proof of concept for its technology. In 2003, the company developed and tested a blood test for RECAF(TM) that is unparalleled in its ability to detect many types of cancer with 90% sensitivity and 95% specificity in the cancers the company has studied to date. No other company can make this claim; BioCurex has superb technology.

The types of malignancies in which the assay has been shown to work cover 60% of all types of cancers. Therefore, it is reasonable to suggest that the Serum-RECAF(TM) test could find use in general screening of many populations, enabling an early diagnosis of any of these cancers. Early detection is the key to providing improved prognosis for all cancer patients.

Further, the test should find early use in the monitoring of cancer patients who have received treatment, but who must be regularly evaluated for any recurrence of cancer. Strategic Plan for 2004 * Results from Japanese and French tests for Histo-RECAF biopsy test expected shortly * Continued testing of various cancer types with the company's RECAF technology with timely reporting of results * Discussions currently underway for licensing of BioCurex technologies with strategic alliance partners * Expansion of specific non-disclosure agreements with well-established potential licensees for the exchange of data.

* Intent to finalize -- in 2004 -- a major licensing deal as well as deals with smaller companies for niche applications of the company's unique technology. * Directors and Officers will continue taking shares or options in lieu of salary to maintain cash for research and development.

* Realization of further patents for over 40 claims granted or pending in over 20 countries. (A RECAF patent for China was granted in late 2003) Other patents previously secured in the United States, Australia and Russia.

* Continued research and development for enhancement of the company's products.

* Planned use of the facilities of large licensees to acquire FDA approval where applicable. Allows their well established pipelines to expedite the process. Approvals for diagnostic tests take place in short time frames

* Once RECAF has developed licensing relationships for its proprietary diagnostic tests, more efficacies will be developed for cancer therapy and management.

* Minimal competition identified due to proprietary nature of BioCurex's technology as well as patent protections in place. BioCurex has worked diligently and progressively to develop, test and improve its technology. The company has demonstrated unique ability to detect various cancers with a blood test -- something which has not been possible to date in the world community. In a number of cases, BioCurex has been approached directly by well-established medical testing companies to engage in substantive strategic alliance and/or licensing discussions. The company expects that trend to continue and increase as its products gain more exposure within the medical and oncological communities.

To read more regarding the state of the company, kindly visit its Web site at www.biocurex.com. Contact: BioCurex Inc., Rancho Santa Margarita Dr. Ricardo Moro, 866-884-8669 Fax: 866-437-2277

Press release #2 BioCurex Blood Test Detects 90% of Leading Cancer Killer Monday April 5, 8:30 am ET RANCHO SANTA MARGARITA, Calif.--(BUSINESS WIRE)--April 5, 2004--BioCurex Inc. (OTCBB:BOCX - News) announces results for lung cancer detection using its proprietary Serum-RECAF(TM) blood test. The results confirm 90% sensitivity with 95% specificity*. The findings further substantiate the use of RECAF(TM) as a universal cancer marker with a potential market size of $2 billion per year for all cancers. The study included 32 lung cancer patients and 103 normal donors with statistical verification. Dr. Moro commented: "Lung cancer is a terrible disease. It kills more people than any other type of cancer and it kills in a terrible way, by asphyxiation. It is gut wrenching to realize that even thought this is a preventable disease, the number of new cases and deaths keeps increasing each year. It is well established that early diagnosis results in better prognosis and that is why it was so important to develop a sensitive lung cancer test that catches 90% of cases with only 5% of false positives. Moreover, there is no other blood test that can detect lung cancer at the present time. The ultimate benefit to society could be enormous."

These results are consistent with those obtained for other types of cancer and strengthen the concept of using Serum-RECAF(TM) as a valid test for screening the general populations for cancer. Since lung cancer, as well as many other cancers, is difficult to detect, the overall value of the RECAF technology in human and market terms is significant. Dr. Moro further stated, "It is not well understood by the general public, that we have very few methods available to tell if a person has a cancer. In fact, for most cancers, there are no existing specific tests.

This is why RECAF is such a valuable technology. Even if we could only detect one type of cancer, we would have a significant discovery, but the studies demonstrate that we obtain continued excellent results in many differing types of cancers and at very high detection values. We are very excited about our potential as a biotech company." About lung cancer: Lung cancer is now the most common form of cancer diagnosed in the United States and a major cause of death. Lung cancer accounts for 14% of all cancers and 28% of all cancer deaths. At present, more Americans die from lung cancer than from breast, prostate, and colorectal cancers combined. Lung cancer has surpassed breast cancer as the most common type of cancer in women. Smoking costs the United States approximately $97.2 billion each year in health-care costs and lost productivity. It is directly responsible for 87 percent of lung cancer cases and causes most cases of emphysema and chronic bronchitis. About BioCurex: BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, tumor imaging and therapeutics. The technology identifies a cancer marker known as RECAF(TM), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. To find out more about BioCurex (OTCBB:BOCX - News), visit our website at www.biocurex.com.

A noter que les déclaration de BioCurex sont sous la responsabilité de cette société et n'engage qu'elle même..

Please note that the declaration of BioCurex are under the responsibilities of this company and engage itself only.


Comment trader et s'intéresser à BIOCUREX ??? La réponse est dans notre article ci-dessous.Article dont parle notre lettre confidentielle : [CLIQUEZ ICI] . On peut s'intéresser à BioCurex (OTCBB: BOCX) sur retrait uniquement si retour sur 1,69 $ ..On vendra vers 2,45 $ à court terme. N'oublions pas le marché de cette société est de 2 milliards de $ potentiellement mais c'est une jeune action donc penser à prendre vos bénéfices. Copyright DAYTRADERBUSINESS.COM - Avril 2004 _ article du 07 /04/2003.
==> CI-DESSOUS 1GRAPHIQUES JOURNALIER <== BioCurex (OTCBB: BOCX) vient d'indiquer ses plans stratégiques vendredi soir · Des résultats impressionnants sur la détection du cancer des poumons avec le serum RECAF un test sanguin qui a été annoncé lundi matin. (voir détails en bas). Le management a travaillé avec intelligence et avec succès pour amener le support et d'investisseurs potentiels et futures partenaires. Très recemment la valeur a réagit sur un mouvement de quelques couvertures de positions à découvert (short covering) . Des résultats récents et d'autres à venir vont continuer à valider la technologie et le potentiel de cette société. Quelques chiffres : Inutile de dire, les actions ont augmenté plus et plus rapidement que n'importe qui aurait pu prévoir. Pendant que nous croyons cela il pourrait y avoir quelque retournement à la baisse à ces niveaux, il y n'a pas de doute à long terme, la commercialisation de la technologie diagnostique de BioCurexs pourrait produire des résultats énormes. Comme aujourd'hui la capitalisation du marché fait plafonner la société à 25 millions de $, la commercialisation de sa technologie dans les marchés de test de cancer --ceux valent des milliards de dollars par an de chiffre d'affiaire-- l'achat à long terme est rendu obligatoire. Cela a dit, pour les lecteurs de notre lettre qui ont suivi nos précédents conseils sur ce genre de valeur à haut potentiel de grand bénéfices ont été noté. (VOIR EN BAS DE LA PAGE) Les investisseurs voudront posséder cette action pour les plus futures annonces, de partenaire(s) potentiel(s) et les possibles alliances à venir. Nous aurons une évaluation plus détaillée de cette société de ces activités dans un avenir proche, mais pour le moment, il est important d'indiquer que la prise en considération de la technologie et des développements potentiels en avenir sont extrêmement encourageants. Ces derniers mois l'actualité a été assez calme. Avec les résultats en ce qui concerne la compagnie les tests de biopsie d'Histo-RECAF au japon et France vont bientôt être annoncée, et on parle d'investisseurs potentiels et de partenaires stratégiques, BioCurex s'est déplacé sur les écrans de radar d'investisseur, pas avec progression progressive mais d'un coup. Et nous croyons que les fortunes de cette compagnie singulière continueront à augmenter sur les semaines et les mois prochains. La commercialisation de la technologie de BioCurex est simplement la première étape dans le développement à long terme de thérapies de cancer et de traitements à venir. La patience a été une stratégie extrêmement valorisante pour les investisseurs de cettesociété bien que, jusqu'à ce que récemment, quasiment rien n'a été rendu publique. Comme nous avons dit,ce qui va changer évidemment et comme encore plus d'infos , nous vous en tiendrons informé.. Pour le moment, merci prendre quelques moments pour lire les 2 communiqués de presse ci-dessous. Press release #1 BioCurex: Aggressively Moves Ahead with 2004 Strategic Plan Friday April 2, 4:56 pm ET RANCHO SANTA MARGARITA, Calif.--(BUSINESS WIRE)-- April 2, 2004--Dr. Ricardo Moro, President and CEO, BioCurex Inc. (OTCBB:BOCX - News) released the company's corporate forecast for 2004. The core of BioCurex's technology is the discovery and subsequent patenting related to a molecule found on cancer cells that is practically absent from normal cells or benign tumor cells. The molecule serves as a cancer "marker" that is found on the surface as well as inside a cancer cell. The company has called it RECAF(TM). Initially, the company developed and reported on a tissue test (Histo-RECAF) and received FDA recognition for its ability to detect cancer cells. The product development and subsequent approval provided early proof of concept for its technology. In 2003, the company developed and tested a blood test for RECAF(TM) that is unparalleled in its ability to detect many types of cancer with 90% sensitivity and 95% specificity in the cancers the company has studied to date. No other company can make this claim; BioCurex has superb technology. The types of malignancies in which the assay has been shown to work cover 60% of all types of cancers. Therefore, it is reasonable to suggest that the Serum-RECAF(TM) test could find use in general screening of many populations, enabling an early diagnosis of any of these cancers. Early detection is the key to providing improved prognosis for all cancer patients. Further, the test should find early use in the monitoring of cancer patients who have received treatment, but who must be regularly evaluated for any recurrence of cancer. Strategic Plan for 2004 * Results from Japanese and French tests for Histo-RECAF biopsy test expected shortly * Continued testing of various cancer types with the company's RECAF technology with timely reporting of results * Discussions currently underway for licensing of BioCurex technologies with strategic alliance partners * Expansion of specific non-disclosure agreements with well-established potential licensees for the exchange of data. * Intent to finalize -- in 2004 -- a major licensing deal as well as deals with smaller companies for niche applications of the company's unique technology. * Directors and Officers will continue taking shares or options in lieu of salary to maintain cash for research and development. * Realization of further patents for over 40 claims granted or pending in over 20 countries. (A RECAF patent for China was granted in late 2003) Other patents previously secured in the United States, Australia and Russia. * Continued research and development for enhancement of the company's products. * Planned use of the facilities of large licensees to acquire FDA approval where applicable. Allows their well established pipelines to expedite the process. Approvals for diagnostic tests take place in short time frames * Once RECAF has developed licensing relationships for its proprietary diagnostic tests, more efficacies will be developed for cancer therapy and management. * Minimal competition identified due to proprietary nature of BioCurex's technology as well as patent protections in place. BioCurex has worked diligently and progressively to develop, test and improve its technology. The company has demonstrated unique ability to detect various cancers with a blood test -- something which has not been possible to date in the world community. In a number of cases, BioCurex has been approached directly by well-established medical testing companies to engage in substantive strategic alliance and/or licensing discussions. The company expects that trend to continue and increase as its products gain more exposure within the medical and oncological communities. To read more regarding the state of the company, kindly visit its Web site at www.biocurex.com. Contact: BioCurex Inc., Rancho Santa Margarita Dr. Ricardo Moro, 866-884-8669 Fax: 866-437-2277 Press release #2 BioCurex Blood Test Detects 90% of Leading Cancer Killer Monday April 5, 8:30 am ET RANCHO SANTA MARGARITA, Calif.--(BUSINESS WIRE)--April 5, 2004--BioCurex Inc. (OTCBB:BOCX - News) announces results for lung cancer detection using its proprietary Serum-RECAF(TM) blood test. The results confirm 90% sensitivity with 95% specificity*. The findings further substantiate the use of RECAF(TM) as a universal cancer marker with a potential market size of $2 billion per year for all cancers. The study included 32 lung cancer patients and 103 normal donors with statistical verification. Dr. Moro commented: "Lung cancer is a terrible disease. It kills more people than any other type of cancer and it kills in a terrible way, by asphyxiation. It is gut wrenching to realize that even thought this is a preventable disease, the number of new cases and deaths keeps increasing each year. It is well established that early diagnosis results in better prognosis and that is why it was so important to develop a sensitive lung cancer test that catches 90% of cases with only 5% of false positives. Moreover, there is no other blood test that can detect lung cancer at the present time. The ultimate benefit to society could be enormous." These results are consistent with those obtained for other types of cancer and strengthen the concept of using Serum-RECAF(TM) as a valid test for screening the general populations for cancer. Since lung cancer, as well as many other cancers, is difficult to detect, the overall value of the RECAF technology in human and market terms is significant. Dr. Moro further stated, "It is not well understood by the general public, that we have very few methods available to tell if a person has a cancer. In fact, for most cancers, there are no existing specific tests. This is why RECAF is such a valuable technology. Even if we could only detect one type of cancer, we would have a significant discovery, but the studies demonstrate that we obtain continued excellent results in many differing types of cancers and at very high detection values. We are very excited about our potential as a biotech company." About lung cancer: Lung cancer is now the most common form of cancer diagnosed in the United States and a major cause of death. Lung cancer accounts for 14% of all cancers and 28% of all cancer deaths. At present, more Americans die from lung cancer than from breast, prostate, and colorectal cancers combined. Lung cancer has surpassed breast cancer as the most common type of cancer in women. Smoking costs the United States approximately $97.2 billion each year in health-care costs and lost productivity. It is directly responsible for 87 percent of lung cancer cases and causes most cases of emphysema and chronic bronchitis. About BioCurex: BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, tumor imaging and therapeutics. The technology identifies a cancer marker known as RECAF(TM), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. To find out more about BioCurex (OTCBB:BOCX - News), visit our website at www.biocurex.com. A noter que les déclaration de BioCurex sont sous la responsabilité de cette société et n'engage qu'elle même.. Please note that the declaration of BioCurex are under the responsibilities of this company and engage itself only. Copyright DAYTRADERBUSINESS.COM - Avril 2004 _ article du 07 /04/2003.
AVERTISSEMENT ATTENTION Ceux qui utilisent ces informations dans le but de trader sont entierement responsables de leurs propres actions. Aucune garantie de résultat(s) n'est donnée, et aucune garantie que ces techniques (incluse la technique des 'chandeliers') soient sources de profit ou qu'il n'en résulterait aucune perte. Quiconque utiliserait ces méthodes ne pourra rendre responsable DAYTRADERBUSINESS.COM de quelques façons que ce soit de pertes financières, du stress, et consequences des pertes en resultant.